Last reviewed · How we verify
Administration of DAA-based treatment
Administration of DAA-based treatment is a Direct-acting antiviral (DAA) combination Small molecule drug developed by Ain Shams University. It is currently in Phase 3 development for Chronic hepatitis C virus (HCV) infection, all genotypes.
DAA-based treatment directly inhibits hepatitis C virus (HCV) nonstructural proteins to block viral replication and cure chronic HCV infection.
DAA-based treatment directly inhibits hepatitis C virus (HCV) nonstructural proteins to block viral replication and cure chronic HCV infection. Used for Chronic hepatitis C virus (HCV) infection, all genotypes.
At a glance
| Generic name | Administration of DAA-based treatment |
|---|---|
| Sponsor | Ain Shams University |
| Drug class | Direct-acting antiviral (DAA) combination |
| Target | HCV NS3/4A protease, HCV NS5B polymerase, HCV NS5A protein (depending on specific DAA regimen) |
| Modality | Small molecule |
| Therapeutic area | Virology / Hepatology |
| Phase | Phase 3 |
Mechanism of action
Direct-acting antivirals (DAAs) target specific HCV enzymes (protease, polymerase, NS5A) required for viral replication. By inhibiting these viral proteins, DAAs prevent HCV from reproducing and allow the immune system to clear the infection, achieving sustained virologic response (SVR) and functional cure in the majority of treated patients.
Approved indications
- Chronic hepatitis C virus (HCV) infection, all genotypes
Common side effects
- Fatigue
- Headache
- Nausea
- Diarrhea
Key clinical trials
- The Kentucky Viral Hepatitis Treatment Study (PHASE4)
- Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard Strategy (PHASE4)
- Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021) (PHASE2)
- Re-link HCV in Substance-Use Telemedicine Program
- Development of a Community-based HCV Treatment Completion Intervention Among HCV Positive Homeless Adults (NA)
- Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients (PHASE1, PHASE2)
- Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant (PHASE4)
- Transplanting Hepatitis C Lungs Into Negative Lung Recipients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Administration of DAA-based treatment CI brief — competitive landscape report
- Administration of DAA-based treatment updates RSS · CI watch RSS
- Ain Shams University portfolio CI
Frequently asked questions about Administration of DAA-based treatment
What is Administration of DAA-based treatment?
How does Administration of DAA-based treatment work?
What is Administration of DAA-based treatment used for?
Who makes Administration of DAA-based treatment?
What drug class is Administration of DAA-based treatment in?
What development phase is Administration of DAA-based treatment in?
What are the side effects of Administration of DAA-based treatment?
What does Administration of DAA-based treatment target?
Related
- Drug class: All Direct-acting antiviral (DAA) combination drugs
- Target: All drugs targeting HCV NS3/4A protease, HCV NS5B polymerase, HCV NS5A protein (depending on specific DAA regimen)
- Manufacturer: Ain Shams University — full pipeline
- Therapeutic area: All drugs in Virology / Hepatology
- Indication: Drugs for Chronic hepatitis C virus (HCV) infection, all genotypes